Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials,European Urology

当前位置： X-MOL 学术 › Eur. Urol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials
European Urology ( IF 25.3 ) Pub Date : 2024-05-22 , DOI: 10.1016/j.eururo.2024.04.038
Praful Ravi ₁ , Wanling Xie ₁ , Marc Buyse ₂ , Susan Halabi ₃ , Philip W Kantoff ₄ , Oliver Sartor ₅ , Gert Attard ₆ , Noel Clarke ₇ , Anthony D'Amico ₈ , James Dignam ₉ , Nicholas James ₁₀ , Karim Fizazi ₁₁ , Silke Gillessen ₁₂ , Wendy Parulekar ₁₃ , Howard Sandler ₁₄ , Daniel E Spratt ₁₅ , Matthew R Sydes ₁₆ , Bertrand Tombal ₁₇ , Scott Williams ₁₈ , Christopher J Sweeney ₁₉

Affiliation

Dana-Farber Cancer Institute, Boston, MA, USA.
International Drug Development Institute, Louvain-la-Neuve, Belgium; I-BioStat, Hasselt University, Hasselt, Belgium.
Duke University, Durham, NC, USA.
Convergent Therapeutics, Cambridge, MA, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mayo Clinic, Rochester, MN, USA.
University College London, London, UK.
The Christie NHS Foundation Trust, Manchester, UK.
Dana-Farber Cancer Institute, Boston, MA, USA; Brigham & Women's Hospital, Boston, MA, USA.
University of Chicago, Chicago, IL, USA.
The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK.
Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland.
Queens University, Kingston, Ontario, Canada.
Cedars-Sinai Medical Center, Los Angeles, CA, USA.
University Hospitals Siedman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Peter Maccallum Cancer Centre, Melbourne, Australia.
South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.

Radiotherapy (RT) and long-term androgen deprivation therapy (ltADT; 18–36 mo) is a standard of care in the treatment of high-risk localized/locoregional prostate cancer (HRLPC). We evaluated the outcomes in patients treated with RT + ltADT to identify which patients have poorer prognosis with standard therapy.

中文翻译：